semaglutide glp1 agonists

Sources

1. Trends in glucagon-like peptide 1 receptor agonist prescribing patterns
   “From 2018 to 2023, GLP-1 RA prescribing increased significantly, with semaglutide approved for weight loss rising to 60% share in the nondiabetic obese/overweight group.”
2. GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials
   “GLP-1 receptor agonists significantly increase the likelihood of weight loss versus placebo, with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated.”
3. Semaglutide versus other GLP-1 receptor agonists in patients with MASLD
   “Compared to other GLP-1RAs, semaglutide was associated with a 14% lower risk of primary composite outcomes... reduced risks of all-cause mortality (aHR, 0.68) and major adverse liver outcomes (aHR, 0.79).”
4. Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (OASIS 4)
   “Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks...”
5. A systematic review and meta-analysis of the efficacy and safety of GLP-1 receptor agonists
   “Semaglutide was effective in reducing major adverse cardiovascular events and reducing pain in knee osteoarthritis. Tirzepatide was effective in...”
6. Unraveling the safety profile of GLP-1 receptor agonists
   “This review integrates evidence from preclinical studies, randomized controlled trials (RCTs), and real-world data to systematically evaluate the safety profile ...”
7. Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol
   “This protocol is a randomized, double-blind, placebo-controlled clinical trial designed to test the efficacy of the GLP-1RA, semaglutide, in 200 participants enrolled in an outpatient MOUD program”
8. Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
   “This review compares semaglutide and tirzepatide aims to support precise, equitable, and durable care for people with the disease of obesity.”
9. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials
   “Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of ...”
10. Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases
    “In this work, we systematically evaluate the therapeutic efficacy and AEs of GLP-1 RAs across multiple disease areas through an umbrella review of meta-analyses.”